anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aspects of this invention relate to the fields of molecular biology and medicine. More specifically, disclosed herein are methods for diagnosing, treating, and monitoring subjects with HPV-infected and/or cancer cells. Embodiments disclosed herein relate to methods of reducing the presence of cancer cells (e.g. a tumor by contacting these cells with a miR-34a nucleic acid where it is internalized and subsequently targets cell-cycle regulatory genes such as pl8Ink4c, CDK4, and cyclin E). More embodiments relate to methods of restoring apoptosis in cancer cells. Additional embodiments relate to methods of increasing the amount of a miR-34a nucleic acid in cancer cells. Still more embodiments relate to methods of reducing the presence of pl 8Ink4c in a HPV-infected cell and methods of monitoring the amount of mi-R34a in a subject.
Those in the intervention group will receive eNutriCardio PN advice after completing the eNutriCardio FFQ at baseline only. At weeks 2, 4 and 8 of the study, participants will also receive coaching emails which includes reminders of their PN advice and questions asking them to reflect on their goal progress, if any. This will be in addition to their participation in an NHS CR programme (if they choose to join).
Randomized, open-label, multi-centre study to evaluate the tolerability of the application of a combination of a serum containing human bone marrow stem cell derived growth factor and cytokines (SCR Complex™) and a botanical lipid based occlusive (Bio Cel™) following facial fractional RF treatments using the Venus Viva™ SR system. Each subject will receive 2 treatments separated by a 3-week interval. Subjects will complete a VAS and Tolerability Scale immediately following each treatment. Telephone follow-up calls by the site will ask the subject to respond to the Self-Report Adverse Event Questionnaire 24 and 72 hours after the first treatment and 24 hours after the second treatment. Subjects will complete a Home Tolerability Scale 24 and 72 hours after the first treatment and 24 hours after the second treatment. Subjects will return for the final FU visit and be asked to respond to the Self-Report Adverse Event Questionnaire and complete the Home Tolerability Scale for 72 hours. The investigator will also evaluate the subject's improvement using the GAIS at this visit.
A method and apparatus are provided for treating hydrated material in a fluid that contains water in which a stable nitroxide is attached to the hydrated material. A dynamic nuclear polarization process (DNP) is conducted on the hydrated material whereby to hyperpolarize the water. A polarization cell contains the hydrated material to obtain hyperpolarized water free from the nitroxide. The dynamic nuclear polarization process is conducted using components comprising a tunable, solid state high power X-band driver and an X-band resonator for microwave transmission to the hydrated material. The components can also include a radio-frequency nuclear magnetic resonance probe, a permanent magnet formed to receive the hydrated material, a portable nuclear magnetic resonance spectrometer, and an electron spin resonance detector. The components can be sized to be portable, and include electrical input and output and a lap-size hard-case with access to the electrical input and output.
OBJECTIVES: I. Assess the survival and failure-free survival in poor risk patients with stage IIIA or IIIB non-small cell lung carcinoma treated with concurrent radiation, carboplatin, and etoposide followed by consolidation with paclitaxel. II. Evaluate the response and toxicities associated with this regimen in this group of poor risk patients.

OUTLINE: This is nonrandomized study. Chemotherapy on cycle 1 starts on day 1 with concurrent initiation of radiotherapy. Chemotherapy is given prior to radiotherapy on those days when both treatments are given. Cycle 2 begins on day 29. Carboplatin is administered by 15 minute IV infusions on days 1, 3, 29, and 31. Etoposide (VP-16) is administered after carboplatin by 30 minute IV infusions on days 1-4, and 29-32. Radiation therapy begins within 24 hours of day 1, cycle 1 of chemotherapy. The primary tumor, the adjacent mediastinum, and other targeted lymph nodes are administered radiotherapy daily 5 days a week for 6.5 weeks. After the 2 cycles of chemotherapy and chest radiotherapy, patients who have stable disease, partial response, or complete response receive 3 cycles of paclitaxel. Paclitaxel is administered by 3 hour IV infusions starting 4 weeks after completion of chemotherapy and radiotherapy and repeated every 3-4 weeks (approximately days 71, 92, and 103) for a total of 3 cycles. Patients are followed every month for the first year, every 3 months for the second year, every 6 months for the third year, and then annually thereafter while on treatment. After treatment, patients are followed every 6 months for 2 years and then annually thereafter.

PROJECTED ACCRUAL: There will be 80 patients accrued in this study over 16 months.
Despite the fact the high dose therapy and autologous transplant can prolong life in patients with multiple myeloma (MM), in most studies there appears to be a continuously declining event free survival following auto-transplant indicating that few patients will be cured with this approach. A high percentage of patients the relapse in the post transplant setting will not be candidate for additional chemotherapy. We therefore, are investigating novel strategies for controlling their disease in the post transplant setting. The key theoretical issue for this study is whether concomitant Trisenox would permit the use of less toxic doses of Velcade, resulting in a less toxic but equally effective regimen.

Phase I of this study uses dose escalation to estimate the maximum tolerated dose of Arsenic, Ascorbic Acid and Velcade. Phase II is a subsequent treatment phase using the maximum tolerated dose from Phase I. In the absence of treatment delays due to adverse events, treatment may continue for 6 cycles, plus two additional cycles if patient has achieved a good response.
A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). This is a Multi-center, prospective, open-label, single-group study. NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use. All enrolled subjects will be treated with up to two injections of NKA at least 6 months apart. Up to 30 subjects undergoing NKA injection will be enrolled into the study. Patients who have received a single injection of NKA under previous research protocols may enroll in this clinical trial to receive a single additional implantation. Patients who have never received an NKA injection may enroll in this clinical trial for up to a total of two (2) NKA injections, temporally spaced at least 6 months apart. All biopsies are to be taken from a single kidney, and all NKA injections are to be given into the kidney that was biopsied.

Patients who complete screening procedures satisfying all I/E criteria will be enrolled into the study immediately prior to the injection. Patients who do not meet all criteria before injection will be considered screen failures. Once a patient has been injected, the patient will have completed treatment and every effort should be made to ensure the patient completes all follow-up visits. Injection dates for the first 3 patients receiving their second NKA injection will be staggered by a minimum of 3 week intervals to allow for assessment of acute adverse events and other safety parameters by a Data Safety Monitoring Board (DSMB). At the completion of the follow-up visits, patients will continue in a long-term observational follow-up period. Patients will be followed for a total of 36 months following the last NKA injection under this protocol, whether the first or second injection.
Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
FIELD: chemistry. ^ SUBSTANCE: composite structure includes a substrate and a liquid in contact with the substrate. The substrate contains nonwoven material, foam plastic or combinations thereof and has basic mass from 15 to 500 g per square metre. The composite structure has bending rigidity less than 1000 mNcm. The method of producing a composite structure having at least one substrate layer and at least one layer containing foam plastic with open pores involves applying foam onto a substrate, where the foam contains water and a thermoplastic polymer; and removing at least a portion of the water from the foam to form foam plastic. ^ EFFECT: obtaining napkins with higher softness and elasticity while preserving strength, integrity, flexibility and resistance to crushing. ^ 54 cl, 16 ex, 6 tbl, 13 dwg
Wound will be covered with negative pressure dressings that are composed of a sterile foam dressing surrounded by an occlusive film that adheres to the nearby, normal skin. Suction is applied to the dressing and a draining tube connect to a wall fixed assisted vacuum canister.

Patients will be provided with paper chits with A or B marked on it. Patients picking up A chit will be dealt as A group where wound will be covered with VAC dressings only where by patients picking up B chit will be dealt as B group where wound will be covered with a single layer of Ag+ hydrocolloid dressings. Such pattern of dressing will be followed in every change of dressing in 48 hours. The wound site will be photographed after every change of dressings. The wound site will be photographically monitored by a team of plastic surgeons to assess granulation tissue, by noting the size of wound, color and shine of granulation tissue and edema.
A total of 40 patients enrolled in the study from outpatient clinics were included. Two groups were formed, namely 'aerobic exercise' and 'isokinetic exercise' groups. Using modified Bruce protocol, effort capacities were measured with Humac Norm Cybex dynamometer, 6 min. walking distance and MSQOL-54 scale were used to assess the quality of life. The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise. Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study. The exercise program was applied for 8 weeks with 3 repetitions per week.

Assessment of exercise capacity (effort capacity) was performed by applying the Norav Trackmaster TMX 425 Treadmill Exercise Device by applying Modified Bruce protocol. Patients' total exercise times were expressed in seconds. Indirect maximum amount of oxygen volume (VO2 max) values were calculated using heart rate obtained with submaximal treadmill exercise.All the cases participating in the study were compared in terms of the pre-treatment MSQoL-54 scale and the MSQoL-54 scale subscale.
Optimal treatment with Clopidogrel and Aspirin is critical for preventing complications after implantation of drug-eluting stents (DES). The premature cessation of Clopidogrel is a well recognized factor of thrombosis of stents, especially DES. Indeed, there remains a large portion of patients that prematurely stop clopidogrel. No study has demonstrated that a therapeutic management program could improve patient compliance to their antiplatelets. Through an open-label clinical study, two groups of patients who just received their DES will be compared: one with the usual protocol (consisting of seeing the cardiologist 6 weeks after the intervention) and one with the normal care supplemented by a simple and efficient follow-up (consisting of phone calls at 7 days, 1 month, 6 months and 9 months explaining the importance of antiplatelet therapy, evaluating the health of the patient and well received prescription from the pharmacy). Patients in both groups will receive a prescription to Clopidogrel and Aspirin (for 1 month), with 11 renewals.
This randomized double blind clinical trial compares the efficacy of buprenorphine maintenance treatment (BMT) and naltrexone maintenance treatment (NMT) for recently detoxified opioid dependent patients (N=130; 65 heroin dependent, 65 opium dependent-Specific Aim 1). Manual-guided, HIV risk reduction and drug counseling (DC-HIV) is provided to all patients as the platform psychotherapy. Maintenance treatment is provided for 12 weeks to all patients; patients may also continue to receive maintenance treatment for an additional 12 weeks following the initial treatment period. Primary outcome measures, assessed by twice weekly urine toxicology testing and self-report during the first 12 weeks and monthly during the 12-week extension, include resumption of heroin use, 1 and 3 weeks continuous relapse and reductions in HIV risk behaviors. The project will also evaluate the characteristics of treatment-seeking opioid addicts in Iran (including specific risk behaviors and patterns of HIV risk behaviors; prevalence of psychiatric and other medical comorbidity; and patterns of social, family, vocational, and criminal activity and service needs-Specific Aim 2). This data will be used to revise the DC-HIV manual to address the specific circumstances and risk behaviors of opioid addicts in Iran and to provide data regarding any differential response of opium compared to heroin addicts to BMT or NMT. Finally, the project will also provide clinical training for health professionals and training and mentoring in drug abuse treatment and HIV prevention research to clinical researchers who will continue development, implementation, evaluation and dissemination of HIV prevention and drug abuse treatment approaches in Iran after the project ends (Specific Aim 3). The Institute for Cognitive Science Studies will collaboratively fund the project and lead subsequent dissemination and drug abuse and HIV risk reduction efforts in Iran.
Interventions to strengthen men's roles as providers, as fathers, and as co-parents have typically been addressed in separate intervention and research silos. The TRUE Dads program proposes a unique integration of employment, fathering, and co-parenting services, with the overarching goal of strengthening fathers and the family unit by: 1) increasing fathers' economic stability and self-sufficiency, 2) enhancing the quantity and quality of father's engagement with their children, 3) improving the quality of the collaborative relationship between fathers and mothers or men and their co-parenting partners, 4) improving the relationship quality of fathers in their intimate partner relationships (with the co-parent or new partner), and 5) positively affecting children's behavior and development.

Twelve hundred fathers will be recruited for the study. After an initial interview of the fathers and their co-parenting partners, who will complete Baseline survey, 720 of the 1,200 fathers and co-parents will be assigned to the TRUE Dads intervention (Program track), and 480 to a no-treatment control condition (Study track). Participants will be informed that the program consists of participation in a series of 12 three-hour meetings. Those 12 sessions include six meetings covering a core fatherhood curriculum, attended with the co-parent, combined with one of three intensives selected by the father: a) six sessions with an emphasis on employment, b) six sessions with an emphasis on building healthy romantic relationships with the co-parent, or c) six sessions with an emphasis on parenting with a participating co-parent. Participants in the Program track may be referred for additional employment, mental health, or other needed services. Both program and control participants (fathers and co-parents) will fill out a Follow-up survey one year from their entrances into the study.
Certain adverse clinical events, some life-threatening, are a direct consequence of physical dependence to alprazolam. These include a spectrum of withdrawal symptoms; the most important is seizure (see DRUG ABUSE AND DEPENDENCE). Even after relatively short-term use at the doses recommended for the treatment of transient anxiety and anxiety disorder (ie, 0.75 to 4.0 mg per day), there is some risk of dependence. Spontaneous reporting system data suggest that the risk of dependence and its severity appear to be greater in patients treated with doses greater than 4 mg/day and for long periods (more than 12 weeks). However, in a controlled postmarketing discontinuation study of panic disorder patients , the duration of treatment (three months compared to six months) had no effect on the ability of patients to taper to zero dose. In contrast, patients treated with doses of alprazolam greater than 4 mg/day had more difficulty tapering to zero dose than those treated with less than 4 mg/day.
Although the viral nature of videos that capture violent and racialized policing of Black Americans in the United States can increase awareness, exposure to race-based violence can result in vicarious traumatization, particularly among Black Americans. The relationship between anticipatory traumatic reactions (ATRs) and racial identity attitudes is not clearly addressed in the extant body of literature. The current study addresses this research disparity by first analyzing group mean differences among Black Americans (N = 138) who were assigned to audiovisual, written, and imaginal exposure groups. The current study also used a cluster analysis of Black Americans to examine the differences between racial identity attitudes and ATRs following media exposure to undue police violence. Results from the study indicated that no differences in ATRs existed based on types of media exposure. Significant differences across three racial identity clusters existed between ATR in association with attitudes of assimilation, miseducation, self-hatred, anti-dominance, and ethnic-racial salience. Findings from the study suggest that mental health professionals should attend to racial identity attitudes as a relevant factor in how Black American clients experience the psychological impact of media exposure to undue police violence.
The invention relates to biodegradable recombinant human serum albumin amphipathic derivatives and preparation and application of a medicinal composition thereof. For the derivatives, alkyl is introduced onto a recombinant human serum albumin skeleton, so that the recombinant human serum albumin skeleton has amphipathy, and is automatically assembled to form nano micelles in water. The biodegradable recombinant human serum albumin amphipathic derivatives have the characteristics that: a medicament can be coated by double interaction between a hydrophobic alkyl (acyl) chain and a recombinant human serum albumin molecular hydrophobic chain and the medicament; and the capability of coating the medicament by using recombinant human serum albumin is obviously improved. Auxiliary materials have high safety. Diseases can be prevented from spreading by protein sources. The biodegradable recombinant human serum albumin amphipathic derivatives can be used as vectors of an organic medicament, an insoluble or slightly soluble medicament and an amphipathic medicament and are used for intravascular or intramuscular injection, oral administration and cavitary or external administration. The medicinal composition has a simple preparation method and a mature process and is suitable for large-scale continuous production.
Methods and apparatuses for the therapeutic delivery of nicotine for smoking cessation, harm reduction and/or substitution. Furthermore, the devices and methods herein are useful as an alternative, general nicotine delivery system in place of tobacco combustion or high temperature (over 150 degrees C.) products. In addition, the methods and devices herein are useful for the therapeutic delivery of a drug, for reducing the cumulative drug dose and hence its potential toxic side effects, while increasing its neurophysiological and/or physiological effects. Moreover, the devices and methods herein are useful for addiction treatment or reduction. In certain embodiments, the methods are adaptable to a medicament delivery device that determines a sequence of drug doses to be delivered. Dose information may be used to control operation of the device.
The invention relates to a preparation method of drug carrier crosslinking-modified rice starch nanocrystals. The method comprises the following steps: (1) preparing starch nanocrystals; (2) sufficiently dispersing the starch nanocrystals in a water phase under ultrasonic actions; and (3) preparing the crosslinking-modified starch nanocrystals. The starch nanocrystals are the restrictive acid hydrolysis product of starch, belong to organic nanoparticles, and can widen the application range of starch. A crosslinking reagent is utilized to carry out crosslinking modification on the rice starch nanocrystals to regulate and control the surface polarity of the starch nanocrystals, thereby increasing the hydrophobicity of the starch nanocrystals, enhancing the drug carrying capacity and stability of the nano starch particles, and lowering the enzymatic decomposability and digestibility of the starch nanocrystals. The method has the advantages of simple production technique and low cost, and has wide industrialized application prospects. The product has adjustable surface polarity, has the nano size, is biodegradable, and thus, is green and environment-friendly.
How should I take nevirapine?

•Nevirapine is always taken in combination with other anti-HIV medications.   
•Take nevirapine exactly as your doctor tells you to take it. Do not change your dose unless your doctor tells you to.   
•You should never take more than one form of nevirapine at the same time. Talk to your doctor if you have any questions.   
•If your child is prescribed nevirapine, your child's doctor will tell you exactly how nevirapine should be taken.  
•You may take nevirapine with or without food.   
•Do not miss a dose of nevirapine. If you miss a dose of nevirapine, take the missed dose as soon as you remember. If it is almost time for your next dose, do not take the missed dose, just take the next dose at your regular time. Do not take two doses at the same time.  
•If you stop taking nevirapine for more than 7 days, ask your doctor how much to take before you start taking it again. You may need to begin taking the nevirapine starting dose again, which is taken 1 time each day for 14 days.
FIELD: medicine. SUBSTANCE: invention relates to methods for preparing an aqueous-spirituous composition based on walnut with milk-wax ripeness and honey with addition of flower pollen and glycine. Method involves separate preparing extracts of green walnuts, flower pollen aqueous-spirituous extracts, green walnuts honey infusion and glycine an aqueous solution followed by their mixing in the following ratio, wt.-%: walnuts an aqueous-spirituous extract, 45.00; flower pollen an aqueous-spirituous extract, 0.03; walnuts honey infusion, 14.00; glycine an aqueous solution, 0.04; alcohol, the balance. Alcohol is added in the concentration providing 40% strength in the composition. Invention can be used for prophylaxis of diseases associated with metabolism disorders, for immunity enhancement and reducing stress states, elimination of iodine deficiency and as antiviral, anthelmintic and antifungal agent. EFFECT: enhanced biological activity of agent, valuable medicinal properties, improved preparing method. 5 cl, 1 tbl, 1 ex